KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to 61.51%.

  • Halozyme Therapeutics' EBITDA Margin rose 526.00% to 61.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 59.33%, marking a year-over-year increase of 898.00%. This contributed to the annual value of 54.32% for FY2024, which is 1361.00% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' EBITDA Margin is 61.51%, which was down 1.03% from 62.15% recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year EBITDA Margin high stood at 68.19% for Q2 2021, and its period low was 22.35% during Q2 2022.
  • Over the past 3 years, Halozyme Therapeutics' median EBITDA Margin value was 50.67% (recorded in 2024), while the average stood at 50.22%.
  • Per our database at Business Quant, Halozyme Therapeutics' EBITDA Margin skyrocketed by 6,970bps in 2021 and then slumped by 4,583bps in 2022.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' EBITDA Margin stood at 55.42% in 2021, then tumbled by 1,437bps to 41.05% in 2022, then skyrocketed by 287bps to 43.92% in 2023, then soared by 1,497bps to 58.89% in 2024, then spiked by 526bps to 61.51% in 2025.
  • Its last three reported values are 61.51% in Q3 2025, 62.15% for Q2 2025, and 53.44% during Q1 2025.